Clinical Implementation Pilot (CIP) Grant Call: Precision Medicine (PM)

Update: Thank you for your interest, the CIP Grant Call is now closed. Successful CIP applicants will be notified via email by the end of October. For enquiries, please contact

Technological advances have allowed us to interrogate the human genome in ways that were never possible before. These tests can help us better predict and diagnose disease and provide optimal outcomes with current therapy. Singapore has initiated a National Precision Medicine programme (NPM) in 2017. In Singapore’s Research Innovation and Enterprise (RIE) 2025 plan, the NPM is a national translational programme prioritised under the Human Health Potential (HHP) domain. One of the goals is to facilitate the incorporation of genetic/genomic tests into clinical pathways that improve patient outcomes while maintaining sustainable per capita cost, optimising healthcare experiences for both providers and patients.

PRECISE is pleased to launch a call for proposals to support CIP projects for clinical application of genetic/genomic tests to diagnose, manage and/or treat a specific patient cohort(s) and/or population for targeted conditions or disease phenotypes, with the overarching aim of the CIP grant call to:

  1. Achieve progress towards the RIE 2025 HHP goals;
  2. Inform policy decision-making for implementation in local healthcare system
Key Highlights

Areas of Interest
  1. Specific areas of interest include conditions or disease phenotypes that require the use of genetic/genomic tests in their clinical pathway to guide diagnosis, management and/or treatment. The genetic/genomic test of interest will focus on molecular-based tests that measure alterations in germline DNA sequence or structure (through sequencing, genotyping or cytogenetics, which may include techniques such as Multiplex Ligation-dependent probe amplification, Fluorescence in situ hybridization).
    1. We do not favour and will not consider: Proposals that do not involve the use of molecular-based tests outlined in point (a) in its clinical pathway to guide diagnosis, management and/or treatment for the conditions or disease phenotypes under consideration.
  2. Focus will also be on clinical pathways that will result in a change to the current screening and/or therapeutic strategy based on the result of the genetic/genomic test. There should be some prior belief that the strategy is likely to improve patient outcomes, reduce healthcare utilisation and/or costs, and/or enhance efficiency in healthcare delivery, preferably supported by established guidelines or studies where available.
    1. We favour: Proposals that involve pathways where there is uncertainty about the optimal way to implement the pathway in Singapore, or uncertainty about the acceptance of clinicians and/or patients to the new pathway in Singapore, or where we need additional data to evaluate costs and benefits of the new pathway in the local healthcare system.
    2. We do not favour and will not consider: Proposals that involve experimental strategies of unclear efficacy or have not been approved for use in humans for the conditions or disease phenotypes under consideration, or proposals that involve genotyping cohorts to study gene-disease association without addressing the uncertainties outlined in point (bi).
Project Teams
  1. The Corresponding Principal Investigator (PI) must hold a primary appointment in, and be salaried by a public healthcare institution (PHI), Academic Medical Centre, an Institute of Higher Learning or Research Institute in Singapore.
  2. Project teams must include a Clinical co-PI who is prepared to champion implementation of the clinical pathway in the healthcare system and drive pilot implementation of the programme, and must include a second co-PI who is experienced in health economics and/or health technology assessment to support economic evaluation of the programme. Project teams are also expected to work closely with PRECISE health economics team and its network for the implementation and economic evaluation of the programme.
Timetable of Events

For all interested applicants
Grant call launch (application start date)29 Jul 2021
Application submission deadline23 Sep 2021
Application review & shortlistingEnd Sep – end Oct 2021
Notification of shortlisting outcome to all applicantsIn the week of 25 Oct 2021
For shortlisted applicants only
Proposal workshop (compulsory attendance for co-PIs)15 Nov 2021 (tentative)
Submission deadline for revised proposals15 Dec 2021 (tentative)
Presentation at Final Review17 Jan 2022 (tentative)
For successful applicants
Funding decisionJan 2022 – Feb 2022
Letter of awardEnd Feb 2022 (tentative)
Resource materials for download
  1. Recorded session of CIP virtual roadshow & CIP virtual roadshow slide deck

    Applicants are strongly encouraged to attend the CIP virtual roadshow before submitting a proposal; the deck outlines the scope of the CIP grant call, review process, evaluation criteria, and other details necessary for your understanding.

  2. FAQ

    Applicants may refer to the list of common FAQs or reach out to us if you require further assistance at

  3. CIP application form template

    Applicants should submit their proposals using the CIP application form template and email submission to

  4. Industry resource list

    Applicants may access the industry resource list if there is interest to explore industry collaboration for your CIP application, or reach out to us at

  5. Budget Impact Model template

    Applicants may reference the Budget Impact Model template to guide the design of their budget impact model for the CIP, if applicable. The Budget Impact Model template is created by the Agency for Care Effectiveness (ACE), Singapore’s national Health Technology Assessment Agency, residing within the Ministry of Health (MOH). Reproduction of this in any material form is prohibited without the prior written permission from ACE. Find out more about ACE

  6. What does an HTA agency do?

    With permission from HITAP. Applicants may access video for an introduction to the role of health technology assessment (HTA) and economic evaluation in informing decision for clinical adoption and reimbursement of health technologies. Please reach out to us if you need support or advice on HTA and economic evaluation for your CIP application at

  7. Guidelines & terms and conditions governing this grant

    Applicants should take note that there is no provision of indirect costs from the grant, and refer documents for further details on funding terms and conditions.

Other Information
  1. Up to 5 CIP projects will be awarded, for a period of 2 years (non-extendable).
  2. Funding of up to S$1.5 million to support the cost of programme implementation and evaluation for each CIP project; additional supplementary funding quantum of up to S$3 million will be available to support collaborative supplementary project(s) between shortlisted applicants (there is no provision of indirect costs from the grant).
  3. We invite applicants to join our LinkedIn group (PRECISE_Clinical Innovation) to be kept abreast of our initiatives for the call.
  4. Feel free to email us at to leave us your questions and connect.

Update: Thank you for your interest, the CIP Grant Call is now closed. Successful CIP applicants will be notified via email by the end of October. For enquiries, please contact